Madrigal Pharmaceuticals Community
NasdaqGS:MDGL Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 15 Analysts
FDA Approval Will Expand MASH Treatment Market Reach
Key Takeaways First FDA-approved MASH treatment and strong U.S. market launch position Madrigal Pharmaceuticals for significant revenue growth. Strategic team enhancements and international market expansion efforts could bolster efficiencies and enhance future net margins.
View narrativeUS$417.60
FV
24.5% undervalued intrinsic discount82.53%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
1 day ago author updated this narrative